Compare BridgeBio Pharma Inc (BBIO) vs KKR & Co Inc (KKR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs KKR & Co Inc — how do they compare? BridgeBio Pharma Inc trades at $72.59 (market cap $14.18B), while KKR & Co Inc trades at $101.94 (market cap $90.54B). The key difference: KKR & Co Inc is far larger — about 6.4× BridgeBio Pharma Inc's market cap, and KKR & Co Inc pays a 0.77% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | KKR | |
|---|---|---|
Market Cap | $14.18B | $90.54B |
Sector | Health | Financials |
52-Week High | $90.17 | $149.34 |
52-Week Low | $49.00 | $83.88 |
Enterprise Value | $15.95B | $13.10B |
Dividend Yield | — | 0.77% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $76.08, up 1.77% on the day, amid a bearish technical signal despite strong analyst buy ratings. The company shows explosive revenue growth, with 2025 revenue reaching $502.08M, but remains deeply unprofitable with a net income margin of -144.39%. Recent news highlights clinical progress for acoramidis in ATTR-CM and infigratinib in achondroplasia, though quarterly EPS misses and negative cash flows from operations pose challenges.
The investment case hinges on commercial execution and pipeline catalysts offsetting high losses and a premium valuation. With 89% analyst buy ratings and a $106.82 consensus price target, Wall Street sees significant upside, but risks include sustained cash burn, competitive pressures, and the need for successful drug launches to justify the current P/S ratio of 19.73.
KKR trades at $104.09, down 1.55% today, amid a bearish technical signal. Recent earnings show two beats (Q1 and Q2 2026) and one miss (Q4 2025), with Q3 2026 results pending. The company reported $19.21B revenue and $2.37B net income for 2025, with a net income margin of 14.97%. Key developments include the $17B sale of USI to Aon and a $2B acquisition of A1 Garage Door Service.
Outlook is supported by strong analyst consensus (24 buys, 0 sells) and a $130.22 price target, implying 25% upside. Risks include volatile cash flows, high debt levels, and regulatory scrutiny from a recent $250M penalty. The stock offers growth potential from strategic deals but faces execution and market risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About KKR & Co Inc
KKR is one of the world's largest alternative asset managers, with $490.7 billion in total assets under management, including $384.5 billion in fee-earning AUM, at the end of June 2022. The company has two core segments: asset management (which includes private markets--private equity, credit, infrastructure, energy and real estate--and public markets--primarily credit and hedge/investment fund platforms) and insurance (following the February 2021 purchase of a 61.5% economic stake in Global Atlantic Financial Group, which is engaged in retirement/annuity and life insurance lines as well as reinsurance). On the asset management side, private markets account for 50% of fee-earning AUM and 70% of base management fees, while public markets account for 50% and 30%, respectively.
Read more on KKR →
